Evidence map›Paper›PMID 40778362›Full record

ArticleOphthalmology science

Predicting Progression to Vision-Threatening Complications in Diabetic Retinopathy.

C Quentin Davis, Nadia K Waheed, Mitchell Brigell

Abstract read
In one paragraph

Article in Ophthalmology science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

C Quentin DavisLKC Technologies, Inc., Gaithersburg, Maryland.
Nadia K WaheedNew England Eye Center, Boston, Massachusetts.
Mitchell BrigellIndependent Contractor, Formally of Aerpio Pharmaceuticals, Cincinnati, Ohio.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To characterize the performance of 56 parameters from electroretinography (ERG)/pupillometry, color fundus photography (FP), OCT angiography (OCTA), and ultra-widefield fluorescein angiography (UWF-FA) for predicting which subjects with nonproliferative diabetic retinopathy (NPDR) will progress to vision-threating complications (VTCs) within 48 weeks. Design: A longitudinal prospective study from 44 trial sites in the United States. Participants: Subjects had moderate-to-severe NPDR and no center-involved diabetic macular edema. Among the 162 subjects, the mean age was 57 years and 58% were male. Intervention: Although this study tested an experimental drug, there was no indication of a treatment effect. Results are analyzed over all subjects regardless of study treatment. Main Outcome Measures: Specialized reading centers measured 56 parameters from 4 testing modalities (ERG/pupillometry, FP, OCTA, and UWF-FA) to evaluate diabetic retinopathy (DR) status. Kaplan-Meier analysis and a Cox proportional hazards model were applied to each parameter to identify significant predictors of progression to VTC, defined as progression to proliferative DR, diabetic macular edema, or treatment thereof. Results: Of the 56 parameters, the strongest predictor of progression in the following 48 weeks was the RETeval DR score, which combines ERG and pupil response. A DR score ≥26.9 had a relative risk (RR) of 5.6 ( Conclusions: Both functional (ERG, pupil response) and structural (FP, OCTA, UWF-FA) testing can predict progression to VTC from DR, with the DR score having the best predictive capability. These results suggest it is possible to improve the DR staging system which in turn may enable better allocation of health care resources. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

Diabetic retinopathyERGOCT angiographyPupillometryUltra-widefield fluorescein angiography

Identifiers

PMID40778362
PMCPMC12329116

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.